Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer
1997

Tumor Marker Concentration Predicts Treatment Failure in Testicular Cancer

Sample size: 669 publication Evidence: high

Author Information

Author(s): R de Wit, R Sylvester, C Tsitsa, PHM de Mulder, DT Sleyfer, WW ten Bokkel Huinink, SB Kaye, AT van Oosterom, E Boven, K Vermeylen, G Stoter

Primary Institution: Rotterdam Cancer Institute

Hypothesis

Is the serum half-life of tumor markers a reliable predictor of treatment failure in patients with disseminated non-seminomatous testicular cancer?

Conclusion

Initial serum concentrations of HCG and AFP are significant predictors of treatment failure, while their half-lives are not.

Supporting Evidence

  • 42% of patients had normal HCG and 37% had normal AFP at the start of chemotherapy.
  • Initial marker concentrations of HCG and/or AFP ≥ 1000 IU 1-1 were highly significant prognosticators for treatment failure.
  • Half-lives of HCG and AFP did not accurately predict treatment failure.

Takeaway

Doctors can tell if chemotherapy will work better by looking at certain blood markers at the start, rather than how long those markers stay in the body.

Methodology

The study analyzed serum half-lives of HCG and AFP during chemotherapy and their relationship with treatment failure in 669 patients.

Limitations

Half-lives could not be calculated for patients whose markers normalized before day 22.

Participant Demographics

Patients with disseminated non-seminomatous testicular cancer treated with cisplatin combination chemotherapy.

Statistical Information

P-Value

p=0.001 for HCG; p<0.001 for AFP

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication